CytoDyn (CytoDyn) ROCE % : 0.00% (As of Feb. 2024)

View and export this data going back to 2005. Start your Free Trial

What is CytoDyn ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. CytoDyn's annualized ROCE % for the quarter that ended in Feb. 2024 was 0.00%.

CytoDyn ROCE % Historical Data

The historical data trend for CytoDyn's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytoDyn ROCE % Chart

CytoDyn Annual Data

Trend

May14

May15

May16

May17

May18

May19

May20

May21

May22

May23

ROCE %

Get a 7-Day Free Trial

CytoDyn Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
ROCE %	Get a 7-Day Free Trial															-	-	-	-	-

CytoDyn ROCE % Calculation

CytoDyn's annualized ROCE % for the fiscal year that ended in May. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: May. 2023 )		(A: May. 2022 )		(A: May. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: May. 2023 )		(A: May. 2022 )		(A: May. 2023 )
	=	-73.074	/	( ( (29.185 - 123.161)	+	(11.292 - 119.796) )	/ 2 )
	=	-73.074	/	( (-93.976	+	-108.504)	/ 2 )
	=	-73.074	/	-101.24
	=	72.18 %

CytoDyn's ROCE % of for the quarter that ended in Feb. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Feb. 2024 )		(Q: Nov. 2023 )		(Q: Feb. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Feb. 2024 )		(Q: Nov. 2023 )		(Q: Feb. 2024 )
	=	-41.44	/	( ( (9.24 - 123.41)	+	(10.27 - 129.476) )	/ 2 )
	=	-41.44	/	( ( -114.17	+	-119.206 )	/ 2 )
	=	-41.44	/	-116.688
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Feb. 2024) EBIT data.

CytoDyn (OTCPK:CYDY) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

CytoDyn ROCE % Related Terms

Thank you for viewing the detailed overview of CytoDyn's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

CytoDyn (CytoDyn) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytoDyn Inc (OTCPK:CYDY) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

296:Germany

Address

1111 Main Street, Suite 660, Vancouver, WA, USA, 98660

Website

https://www.cytodyn.com

CytoDyn Inc is a US-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The lead product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.

Executives

Tyler Blok	officer: EVP of Legal Affairs	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Stephen M Simes	director
Ryan Dunlap	director	310 N. STATE STREET, SUITE 208, LAKE OSWEGO OR 97034
Arvin Cyrus Arman	officer: President	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Karen J Brunke	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Tanya Durkee Urbach	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Lishomwa C Ndhlovu	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Harish Seethamraju	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Alan P Timmins	director	1111 MAIN STREET, SUITE 600, VANCOUVER WA 98660
Gordon A Gardiner	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Samir Rashmikant Patel	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Antonio Migliarese	officer: Chief Financial Officer	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Chris P Recknor	officer: Chief Operating Officer	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Michael D. Mulholland	officer: CFO, Treasurer and Secretary	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Jordan G Naydenov	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660